New pill takes aim at aggressive tumors with genetic flaw
NCT ID NCT06710847
First seen Feb 02, 2026 · Last updated May 25, 2026 · Updated 15 times
Summary
This study tests an experimental pill (GSK4418959) in adults with advanced solid tumors that have specific genetic changes (dMMR or MSI-H). The drug targets a DNA repair protein to try to shrink tumors. The trial will check safety, side effects, and how well the drug works alone or with another cancer medicine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Los Angeles, California, 90095, United States
-
GSK Investigational Site
Denver, Colorado, 80218, United States
-
GSK Investigational Site
Detroit, Michigan, 48201, United States
-
GSK Investigational Site
New York, New York, 10016, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19104, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19107, United States
-
GSK Investigational Site
Melbourne, Victoria, 3000, Australia
-
GSK Investigational Site
Brussels, 1200, Belgium
-
GSK Investigational Site
Ghent, 9000, Belgium
-
GSK Investigational Site
Leuven, 3000, Belgium
-
GSK Investigational Site
Chiba, 277-8577, Japan
-
GSK Investigational Site
Shizuoka, 411-8777, Japan
-
GSK Investigational Site
Tokyo, 104-0045, Japan
-
GSK Investigational Site
Tokyo, 135-8550, Japan
-
GSK Investigational Site
Amsterdam, 1066 CX, Netherlands
-
GSK Investigational Site
Daegu, 41404, South Korea
-
GSK Investigational Site
Gyeonggi-do, 10408, South Korea
-
GSK Investigational Site
Seoul, 03080, South Korea
-
GSK Investigational Site
Barcelona, 08023, Spain
-
GSK Investigational Site
Barcelona, 08035, Spain
-
GSK Investigational Site
Madrid, 28040, Spain
-
GSK Investigational Site
Málaga, 29010, Spain
Conditions
Explore the condition pages connected to this study.